World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
98
Citations
50495
World Ranking
8762
National Ranking
4519

Adam Brufsky publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Adam Brufsky sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 681 publications — 79th percentile

79% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Adam Brufsky D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Adam Brufsky sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 98 D-Index — 57th percentile

57% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Adam Brufsky is affiliated with the University of Pittsburgh in the United States and has a research focus primarily in the fields of Medicine and Biochemistry, Genetics, and Molecular Biology. Their work spans multiple subfields, notably Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Genetics, and Infectious Diseases.

The scientist has contributed extensively to research on advanced breast cancer therapies and related topics. Their main areas of investigation include:

  • Advanced Breast Cancer Therapies
  • Breast Cancer Treatment Studies
  • HER2/EGFR in Cancer Research
  • Cancer Treatment and Pharmacology
  • Cancer Genomics and Diagnostics
  • SARS-CoV-2 and COVID-19 Research
  • Chronic Lymphocytic Leukemia Research

Brufsky's publications have appeared frequently in recognized medical and oncology journals. The top venues for their work include:

  • Cancer Research
  • Journal of Clinical Oncology
  • Annals of Oncology
  • Clinical Cancer Research
  • ESMO Open

Among the recent and notable papers associated with the field of breast cancer and oncology are:

  • "Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer" (2021), New England Journal of Medicine
  • "Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study" (2020), The Lancet Oncology
  • "Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial" (2020), Journal of Clinical Oncology
  • "TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes" (2020), Journal of Clinical Oncology
  • "Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer" (2022), Annals of Oncology

Collaboration is a significant aspect of Brufsky's research, with frequent co-authors including Hope S. Rugo, Sara A. Hurvitz, Joyce O'Shaughnessy, Lynn McRoy, and Rachel M. Layman. These collaborators indicate active engagement in oncology and breast cancer research communities.

Best Publications

  • Comprehensive molecular portraits of human breast tumours

    Daniel C. Koboldt;Robert S. Fulton;Michael D. McLellan;Heather Schmidt

  • Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer

    Joseph A. Sparano;Robert J. Gray;Della F. Makower;Kathleen I. Pritchard

  • Prospective Validation of a 21-Gene Expression Assay in Breast Cancer

    J. A. Sparano;R. J. Gray;D. F. Makower;K. I. Pritchard

  • RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

    Nicholas J. Robert;Véronique Diéras;John Glaspy;Adam M. Brufsky

  • Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

    Aditya Bardia;Sara A Hurvitz;Sara M Tolaney;Delphine Loirat

  • The CAG repeat within the androgen receptor gene and its relationship to prostate cancer.

    Edward Giovannucci;Meir J. Stampfer;Krishna Krithivas;Myles Brown

  • Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer

    Nancy U Lin;Véronique Diéras;Devchand Paul;Dominique Lossignol

  • Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

    Sandra M Swain;Sandra M Swain;David Miles;Sung-Bae Kim;Young-Hyuck Im

  • Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.

    Stephen Chia;William Gradishar;Louis Mauriac;Jose Bines

  • Bevacizumab added to neoadjuvant chemotherapy for breast cancer

    Harry D. Bear;Gong Tang;Priya Rastogi;Charles E. Geyer

  • Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus Trastuzumab As Adjuvant Therapy for Patients With Node-Positive, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

    Edward H. Romond;Jong Hyeon Jeong;Priya Rastogi;Sandra M. Swain

  • Zoledronic Acid Inhibits Adjuvant Letrozole–Induced Bone Loss in Postmenopausal Women With Early Breast Cancer

    Adam Brufsky;W. Graydon Harker;J. Thaddeus Beck;Robert Carroll

  • RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

    Adam M. Brufsky;Sara Hurvitz;Edith Perez;Raji Swamy

  • Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.

    Joseph A. Sparano;Robert J. Gray;Peter M. Ravdin;Della F. Makower;Della F. Makower

  • Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With >= 2 HER2-Directed Regimens: Phase III NALA Trial

    Cristina Saura;Mafalda Oliveira;Yin-Hsun Feng;Ming-Shen Dai

  • Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial

    André Robidoux;Gong Tang;Priya Rastogi;Charles E Geyer

  • Cognitive impairment associated with adjuvant therapy in breast cancer.

    Catherine M. Bender;Susan M. Sereika;Sarah L. Berga;Victor G. Vogel

  • Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER

    Adam M. Brufsky;Musa Mayer;Hope S. Rugo;Peter A. Kaufman

  • TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.

    Nadine M Tung;Nadine M Tung;Mark E Robson;Steffen Ventz;Cesar A Santa-Maria

  • Practical guidance for the management of aromatase inhibitor-associated bone loss

    P. Hadji;J.-J. Body;M.S. Aapro;A. Brufsky

Frequent Co-Authors

Hope S. Rugo
Hope S. Rugo University of California, San Francisco
Sandra M. Swain
Sandra M. Swain Georgetown University Medical Center
Steffi Oesterreich
Steffi Oesterreich University of Pittsburgh
Louis Fehrenbacher
Louis Fehrenbacher Kaiser Permanente
Nancy E. Davidson
Nancy E. Davidson University of Washington
Joyce O'Shaughnessy
Joyce O'Shaughnessy Baylor University Medical Center
Susan M. Sereika
Susan M. Sereika University of Pittsburgh
Soonmyung Paik
Soonmyung Paik Yonsei University
Charles E. Geyer
Charles E. Geyer University of Pittsburgh
Sara A. Hurvitz
Sara A. Hurvitz Fred Hutchinson Cancer Research Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those considering studying Medicine in the USA, a variety of related online degrees and alternative career pathways can complement or enhance your primary education. Healthcare is a vast field, and many related disciplines offer outstanding career prospects alongside flexibility and affordability.

Pursuing a Master’s in Healthcare Administration (MHA) is a popular option for students aiming to move into managerial or leadership positions within the healthcare sector. Numerous affordable mha online programs allow you to earn this degree while continuing your current professional or personal commitments.

If your interests lie in advanced nursing practices, you may consider enrolling in cheap dnp online programs to achieve a Doctor of Nursing Practice. This high-level credential can open roles in clinical leadership, education, or specialized care.

Pharmacists are essential members of the healthcare team. Those looking to enter this profession can explore pharm d online programs for an accessible path to a Doctor of Pharmacy degree from accredited institutions.

For a career at the intersection of healthcare, technology, and administration, consider rhia certification programs online. These programs cover skills necessary for managing patient data and healthcare information systems—an increasingly vital role in modern medicine.

Best Scientists Citing Adam Brufsky

Trending Scientists

Recently Published Articles